Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-Course Radiotherapy Followed by Ivonescimab in pMMR/MSS Mid-Low Rectal Cancer
NCT07162714Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Oct 2025
- Primary completion
- Mar 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab in rectal cancer, sponsored by Zhejiang Cancer Hospital. Primary endpoint: Complete remission rate. Started Oct 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07162714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07162714.